Brivanib is an oral,small molecule dual target tyrosine kinase inhibitor (TKI) of VEGF receptor (VEGFR)and FGF receptor (FGFR) that we have an exclusive license for in mainland China, Hong Kong (China), Macau (China) and Taiwan region from Bristol Myers Squibb Company. Brivanib has been tested in several clinical trials in hepatocellular cancer (HCC) anddemonstrated anti-tumor activity and a manageable safety profile. In the secondquarter of 2017, we initiated a Phase II trial of brivanib as a second-linetreatment for advanced HCC patients in China. The efficacy and tolerability dataof the interim analysis are consistent with previous clinical trials. We believe that brivanib has the potential tobe an effective treatment option for Chinese HCC patients and merits furtherclinical trials in combination with a checkpoint inhibitor.
Mechanism of Action
Brivanib blocks the tyrosine kinase activity of both VEGFR and FGFR. VEGFplays a key role in tumor angiogenesis and aberrations in VEGFR have been shownto have potential in driving tumor growth, promoting angiogenesis, andconferring resistance mechanisms to anti-cancer therapies.